We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia.
- Authors
Uranga MD, Ane; Artaraz MD, Amaia; Bilbao MD, Amaia; Quintana MD, Jose María; Arriaga MD, Ignacio; Intxausti MD, Maider; Lobo MD, Jose Luis; García MD, Julia Amaranta; Camino MD, Jesus; España MD, Pedro Pablo; Uranga, Ane; Artaraz, Amaia; Bilbao, Amaia; Quintana, Jose María; Arriaga, Ignacio; Intxausti, Maider; Lobo, Jose Luis; García, Julia Amaranta; Camino, Jesus; España, Pedro Pablo
- Abstract
<bold>Background: </bold>The optimal duration of antibiotic treatment for community-acquired pneumonia (CAP) is not well established. The aim of this study was to assess the impact of reducing the duration of antibiotic treatment on long-term prognosis in patients hospitalized with CAP.<bold>Methods: </bold>This was a multicenter study assessing complications developed during 1 year of patients previously hospitalized with CAP who had been included in a randomized clinical trial concerning the duration of antibiotic treatment. Mortality at 90 days, at 180 days and at 1 year was analyzed, as well as new admissions and cardiovascular complications. A subanalysis was carried out in one of the hospitals by measuring C-reactive protein (CRP), procalcitonin (PCT) and proadrenomedullin (proADM) at admission, at day 5 and at day 30.<bold>Results: </bold>A total of 312 patients were included, 150 in the control group and 162 in the intervention group. Ninety day, 180 day and 1-year mortality in the per-protocol analysis were 8 (2.57%), 10 (3.22%) and 14 (4.50%), respectively. There were no significant differences between both groups in terms of 1-year mortality (p = 0.94), new admissions (p = 0.84) or cardiovascular events (p = 0.33). No differences were observed between biomarker level differences from day 5 to day 30 (CRP p = 0.29; PCT p = 0.44; proADM p = 0.52).<bold>Conclusions: </bold>Reducing antibiotic treatment in hospitalized patients with CAP based on clinical stability criteria is safe, without leading to a greater number of long-term complications.
- Subjects
COMMUNITY-acquired pneumonia; TREATMENT duration; CLINICAL trials; PROGNOSIS; C-reactive protein
- Publication
BMC Pulmonary Medicine, 2020, Vol 20, Issue 1, pN.PAG
- ISSN
1471-2466
- Publication type
journal article
- DOI
10.1186/s12890-020-01293-6